Nurix Therapeutics Inc NRIX

Healthcare Biotechnology

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

NDAQ:NRIX - Post by User

Nurix Therapeutics Inc

<< Previous

Bullboard Posts

Post by whytestockson Aug 02, 2024 8:46pm

41 Views

Post# 36162272

Where are the Opportunities in (NRIX)

Just In: $NRIX Where are the Opportunities in (NRIX)2024-08-02 12:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...NRIX - Where are the Opportunities in (NRIX)

<< Previous

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features